A retrospective analysis of the Spanish Thoracic Tumor Registry in the 2010s reported that chemoradiotherapy remains the most common treatment modality for patients with stage III NSCLC in greater than one-third of patients, amounting to more than 6000 patients for whom durvalumab may be indicated.26 The number of cases that do not qualify for durvalumab based on PD-L1 tumor proportion score remains unknown. The gene discussed is CD274; the disease is non-small cell lung carcinoma.